Current status of animal-to-human transplantation

Expert Opinion on Biological Therapy

Volumn 5, Issue 11, 2005, Pages 1415-1420

  Zhong, Robert ^b   Platt, Jeffrey L ^a  

^a Mayo Clinic   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Acute vascular rejection; Genetic engineering; Graft rejection; Organ transplantation; Xenotransplantation

Indexed keywords

BLOOD CLOTTING; GENETIC ENGINEERING; GRAFT REJECTION; HUMAN; MULTIPLE ORGAN FAILURE; NONHUMAN; ORGAN TRANSPLANTATION; PROTEIN EXPRESSION; RECIPIENT; REVIEW; RISK FACTOR; THROMBOSIS; XENOGRAFT; XENOTRANSPLANTATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA;

EID: 27644512273     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.11.1415     Document Type: Review

References (55)

1. JABOULAY M: De reins au pli du coude par soutures arterielles et veineuses. Lyon Med. (1906) 107:575-577.
2. ULLMAN E: Tissue and organ transplantation. Ann. Surg. (1914) 60:195-219.
3. CASCALHO M, PLATT JL: Xenotransplantation and other means of organ replacement. Nat. Rev. Immunol. (2001) 1:154-160.
4. CASCALHO M, PLATT JL: The immunological barrier to xenotransplantation. Immunity (2001) 14:437-446. This paper reviews the immunological barriers to xenotransplantation.
5. KHALPEY Z, KOCH CA, PLATT JL: Xenograft transplantation. Anesethesiol. Clin. North Am. (2004) 22:871-875.
6. WILLIAMS JM, HOLZKNECHT ZE, PLUMMER TB, LIN SS, BRUNN GJ, PLATT JL: Acute vascular rejection and accommodation: divergent outcomes of the humoral response to organ transplantation. Transplantation (2004) 78:1471-1478.
7. SAADI S, TAKAHASHI T, HOLZKNECHT RA, PLATT JL: Pathways to acute humoral rejection. Am. J. Pathol. (2004) 164:1073-1080.
8. OGATA K, PLATT JL: Cardiac xenotransplantation: future and limitations. Cardiology (2004) 101:144-155.
9. PLATT JL, VERCELLOTTI GM, LINDMAN BJ, OEGEMA TR JR, BACH FH, DALMASSO AP: Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection. J. Exp. Med. (1990) 171:1363-1368.
10. HOLZKNECHT ZE, KUYPERS KL, PLUMMER TB et al.: Apoptosis and cellular activation in the pathogenesis of acute vascular rejection. Circ. Res. (2002) 91:1135-1141.
11. SAADI S, HOLZKNECHT RA, PATTE CP, STERN DM, PLATT JL: Complement-mediated regulation of tissue factor activity in endothelium. J. Exp. Med. (1995) 182:1807-1814.
12. SAADI S, HOLZKNECHT RA, PATTE CP, PLATT JL: Endothelial cell activation by pore forming structures: pivotal role for IL-1α. Circulation (2000) 101:1867-1873.
13. MCREGOR CG, TEOTIA SS, BYRNE GW et al.: Cardiac xenotransplantation: progress toward the clinic. Transplantation (2004) 78:1569-1575.
14. PLATT JL, VERCELLOTTI GM, DALMASSO AP et al.: Transplantation of discordant xenografts: a review of progress. Immunol. Today (1990) 11:450-456. This paper provides the first suggestion that genetic engineering and accommodation might be applied in xenotransplantation.
15. KOCH CA, KHALPEY ZI, PLATT JL: Accommodation: preventing injury in transplantation and disease. J. Immunol. (2004) 172:5143-5148.
16. GOOD AH, COOPER DK, MALCOLM AJ et al.: Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans. Transplant. Proc. (1992) 24:559-562. This paper first mentions Galα1-3Gal as a potential target of rejection in xenotransplantation.
17. LIN SS, KOOYMAN DL, DANIELS LJ et al.: The role of natural anti-Galα1-3Gal antibodies in hyperacute rejection of pig-to-baboon cardiac xenotransplants. Transpl. Immunol. (1997) 5:212-218.
18. LIN SS, HANAWAY MJ, GONZALEZ-STAWINSKI GV et al.: The role of anti-Galα1-3Gal antibodies in acute vascular rejection and accommodation of xenografts. Transplantation (2000) 70:1667-1674.
19. SACHS DH, SABLINSKI T: Tolerance across discordant xenogeneic barriers. Xenotransplantation (1995) 2:234-239.
20. SABLINSKI T, EMERY DW, MONROY R et al.: Long-term discordant xenogeneic (porcine-to-primate) bone marrow engraftment in a monkey treated with porcine-specific growth factors. Transplantation (1999) 67:972-977.
21. BRACY JL, SACHS DH, IACOMINI J: Inhibition of xenoreactive natural antibody production by retroviral gene therapy. Science (1998) 281:1845-1847.
22. MCCURRY KR, KOOYMAN DL, ALVARADO CG et al.: Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat. Med. (1995) 1:423-427. This paper reports the first transplants using genetically engineered pigs as a source of organs.
23. COZZI E, YANNOUTSOS N, LANGFORD GA, PINO-CHAVEZ G, WALLWORK J, WHITE DJG: Effect of transgenic expression of human decay-accelerating factor on the inhibition of hyperacute rejection of pig organs. In: Xenotransplantation: The Transplantation of Organs and Tissues Between Species. 2nd ed. Cooper DKC, Kemp E, Platt JL, White DJG (Eds), Springer, Berlin, Germany (1997):665-682.
24. COZZI E, BHATTI F, SCHMOECKEL M et al.: Long-term survival of nonhuman primates receiving life-supporting transgenic porcine kidney xenografts. Transplantation (2000) 70:15-21.
25. LAI L, KOLBER-SIMONDS D, PARK KW et al.: Production of α-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science (2002) 295:1089-1092.
26. PHELPS CJ, KOIKE C, VAUGHT TD et al.: Production of alpha 1,3-galactosyltransferase-deficient pigs. Science (2003) 299:411-414.
27. MIYATA Y, PLATT J: Xeno: still stuck without alphaGal. Nat. Biotechnol. (2003) 21:359-360.
28. KUWAKI K, TSENG YL, DOR FJ et al.: Heart transplantation in baboons using alpha 1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat. Med. (2005) 11:29-31. This paper reports the first use of Galα1-3Gal-deficient pigs as a source of cardiac xenografts.
29. YAMADA K, YAZAWA K, SHIMIZU A et al.: Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3- galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nat. Med. (2005) 11:32-34. This paper reports the first use of Galα1-3Gal-deficient pigs as a source of renal xenografts.
30. MCGREGOR CG, DAVIES WR, OI K et al.: Cardiac xenotransplantation: recent preclinical progress with 3-month median survival. J. Thorac. Cardiovasc. Surg. (2005) 130:e844 e841. This paper reports the outstanding outcome of xenografts that express Galα1-3Gal and no evidence of spontaneous, uncontrollable coagulation independent of rejection.
31. CHEN G, QIAN H, STARZL T et al.: Induced anti-non-Gal antibodies lead to acute humoral xenograft rejection in baboons using alpha1,3- galactosyltransferase gene-knockout pigs as kidney donors. Nat. Med. (2005) (In Press). This paper cautions that eliminating Galα1-3Gal, the main target in pigs of the human antibody response, may not impirove the outcome of xenografts.
32. LIN SS, WEIDNER BC, BYRNE GW et al.: The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants. J. Clin. Invest. (1998) 101:1745-1756.
33. BUHLER L, BASKER M, ALWAYN IP et al.: Coagulation and thrombotic disorders associated with pig organ and hematopoietic cell transplantation in nonhuman primates. Transplantation (2000) 70:1323-1331.
34. COWAN PJ, AMINIAN A, BARLOW H et al.: Renal xenografts from triple-transgenic pigs are not hyperacutely rejected but cause coagulopathy in non-immunosuppressed baboons. Transplantation (2000) 69:2504-2515.
35. KUWAKI K, KNOSALLA C, DOR FJ et al.: Suppression of natural and elicited antibodies in pig-to-baboon heart transplantation using a human anti-human CD154 mAb-based regimen. Am. J. Transplant. (2004) 4:363-372.
36. MAZZUCATO M, DE MARCO L, PRADELLA P, MASOTTI A, PARETI FI: Porcine von Willebrand factor binding to human platelet GPIb induces transmembrane calcium influx. Thromb. Haemost. (1996) 75:655-660.
37. LAWSON JH, PLATT JL: Molecular barriers to xenotransplantation. Transplantation (1996) 62:303-310.
38. LAWSON JH, DANIELS L, PLATT JL: The evaluation of thrombomodulin activity in porcine to human xenotransplantation. Transplant. Proc. (1997) 29:884-885.
39. CHEN D, WEBER M, MCVEY JH et al.: Complete inhibition of acute humoral rejection using regulated expression of membrane-tethered anticoagulants on xenograft endothelium. Am. J. Transplant. (2004) 4:1958-1963.
40. DWYER KM, ROBSON SC, NANDURKAR HH et al.: Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J. Clin. Invest. (2004) 113:1440-1446.
41. MENDICINO M, LIU M, GHANEKAR A et al.: Targeted deletion of Fgl-2/fibroleukin in the donor modulates immunologic response and acute vascular rejection in cardiac xenografts. Circulation (2005) 112:248-256.
42. COWAN PJ, AMINIAN A, BARLOW H et al.: Protective effects of recombinant human antithrombin III in pig-to-primate renal xenotransplantation. Am. J. Transplant. (2002) 2:520-525.
43. BYRNE GW, SCHIRMER JM, FASS DN et al.: Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. Am. J. Transplant. (2005) 5:1011-1020.
44. PATIENCE C, TAKEUCHI Y, WEISS RA: Infection of human cells by an endogenous retrovirus of pigs. Nat. Med. (1997) 3:282-286.
45. PATIENCE C, PATTON GS, TAKEUCHI Y et al.: No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys. Lancet (1998) 352:699-701.
46. PARADIS K, LANGFORD G, LONG Z et al.: Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. Science (1999) 285:1236-1241.
47. OGLE BM, BUTTERS KB, PLUMMER TB et al.: Spontaneous fusion of cells between species yields transdifferentiation and retroviral in vivo. FASEB J. (2004) 18:548-550. This paper provides the first evidence of transfer of the endogenous retrovirus of pigs from swine to human cells in vivo.
48. OGLE BM, CASCALHO M, PLATT JL: Biological implications of cell fusion. Nat. Rev. Mol. Cell Biol. (2005) 6:567-575.
49. DALMASSO AP, VERCELLOTTI GM, FISCHEL RJ, BOLMAN RM, BACH FH, PLATT JL: Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. Am. J. Pathol. (1992) 140:1157-1166.
50. YAMADA K, SACHS DH, DERSIMONIAN H: Human anti-porcine xenogeneic T cell response. Evidence for allelic specificity of mixed leukocyte reaction and for both direct and indirect pathways of recognition. J. Immunol. (1995) 155:5249-5256.
51. DORLING A, LOMBARDI G, BINNS R, LECHLER RI: Detection of primary direct and indirect human anti-porcine T cell responses using a porcine dendritic cell population. Eur. J. Immunol. (1996) 26:1378-1387.
52. INVERARDI L, SAMAJA M, MOTTERLINI R, MANGILI F, BENDER JR, PARDI R: Early recognition of a discordant xenogeneic organ by human circulating lymphocytes. J. Immunol. (1992) 149:1416-1423.
53. AL-MOHANNA F, COLLISON K, PARHAR R et al.: Activation of naive xenogeneic but not allogeneic endothelial cells by human naive neutrophils: a potential occult barrier to xenotransplantation. Am. J. Pathol. (1997) 151:111-120.
54. BLAKELY ML, VAN DER WERF WJ, BERNDT MC, DALMASSO AP, BACH FH, HANCOCK WW: Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. Transplantation (1994) 58:1059-1066.
55. BUSTOS M, SAADI S, PLATT JL: Platelet-mediated activation of endothelial cells: implications for the pathogenesis of transplant rejection. Transplantation (2001) 72:509-515.